Patents by Inventor Michael Schrimpf
Michael Schrimpf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220017511Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: February 24, 2021Publication date: January 20, 2022Applicant: AbbVie Inc.Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
-
Publication number: 20210130346Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.Type: ApplicationFiled: April 14, 2017Publication date: May 6, 2021Applicant: AbbVie Inc.Inventors: David Hardee, Jason Brewer, Lisa Hasvold, Dachun Liu, Keith McDaniel, Michael Schrimpf, George Sheppard
-
Publication number: 20200255426Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: April 27, 2020Publication date: August 13, 2020Applicant: AbbVie Inc.Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
-
Publication number: 20190345153Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: April 14, 2017Publication date: November 14, 2019Applicant: AbbVie Inc.Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
-
Patent number: 8691865Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L1, L2, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.Type: GrantFiled: May 24, 2011Date of Patent: April 8, 2014Assignee: AbbVie Inc.Inventors: Xenia B. Searle, Ming C. Yeung, Stanley DiDomenico, Andrew O. Stewart, Daria Darczak, Michael Schrimpf, Michael J. Rozema
-
Publication number: 20110281870Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L1, L2, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.Type: ApplicationFiled: May 24, 2011Publication date: November 17, 2011Applicant: ABBOTT LABORATORIESInventors: Xenia B. Searle, Ming C. Yeung, Stanley DiDomenico, Andrew O. Stewart, Daria Darczak, Michael Schrimpf, Michael J. Rozema
-
Publication number: 20080234308Abstract: The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to ?7 nicotinic acetylcholine receptors also are described.Type: ApplicationFiled: September 7, 2006Publication date: September 25, 2008Applicant: Abbott LaboratoriesInventors: Michael Schrimpf, Kevin Sippy, David Anderson, William Bunnelle, Diana Nersesian
-
Publication number: 20080097094Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.Type: ApplicationFiled: December 15, 2007Publication date: April 24, 2008Applicant: Abbott LaboratoriesInventors: Michael Schrimpf, Karin Tietje, Richard Toupence, Jianguo Ji, Anwer Basha, William Bunnelle, Jerome Daanen, Jennifer Frost, Kevin Sippy
-
Publication number: 20080090798Abstract: Heterocyclic substituted aminoazacyclic compounds of formula I Z-R3??I, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.Type: ApplicationFiled: December 12, 2007Publication date: April 17, 2008Applicant: ABBOTT LABORATORIESInventors: Michael Schrimpf, Kevin Sippy, Jerome Daanen, Keith Ryther, Jianguo Ji
-
Publication number: 20070072892Abstract: The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to ?7 nicotinic acetylcholine receptors also are described.Type: ApplicationFiled: September 7, 2006Publication date: March 29, 2007Inventors: Michael Schrimpf, Kevin Sippy, David Anderson, William Bunnelle, Diana Nersesian
-
Publication number: 20070060588Abstract: Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O?; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.Type: ApplicationFiled: June 9, 2006Publication date: March 15, 2007Inventors: Jianguo Ji, Tao Li, Kathleen Mortell, Michael Schrimpf, Diana Nersesian, Liping Pan, William Bunnelle
-
Publication number: 20060217415Abstract: This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: June 29, 2004Publication date: September 28, 2006Applicant: ABBOTT LABORATORIES patent and Trademark DepartmentInventors: Dan Peters, Gunnar Olsen, Elsbert Nielsen, Philip Ahring, Tino Jorgensen, Michael Schrimpf, Kevin Sippy
-
Publication number: 20050245531Abstract: Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O—; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.Type: ApplicationFiled: June 15, 2005Publication date: November 3, 2005Inventors: Jianguo Ji, Tao Li, Kathleen Mortell, Michael Schrimpf, Diana Nersesian, Liping Pan, William Bunnelle
-
Publication number: 20050234031Abstract: Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, Xa and Xb are C, CH, or N, as defined herein, and Rx is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by ?7nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives. Methods of using amino-substituted tricyclic derivatives also are described herein.Type: ApplicationFiled: February 4, 2005Publication date: October 20, 2005Inventors: Michael Schrimpf, Kevin Sippy, Jianguo Ji, Tao Li, Jennifer Frost, Clark Briggs, William Bunnelle
-
Publication number: 20050171079Abstract: Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, and Rx is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives.Type: ApplicationFiled: February 4, 2004Publication date: August 4, 2005Inventors: Michael Schrimpf, Kevin Sippy, Jianguo Ji, Tao Li, Jennifer Pace, Clark Briggs
-
Publication number: 20050101602Abstract: Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.Type: ApplicationFiled: September 16, 2004Publication date: May 12, 2005Inventors: Anwer Basha, William Bunnelle, Michael Dart, Megan Gallagher, Jianguo Ji, Tao Li, Jennifer Pace, Keith Ryther, Karin Tietje, Kathleen Mortell, Diana Nersesian, Michael Schrimpf
-
Publication number: 20050043291Abstract: Heterocyclic substituted aminoazacyclic compounds of formula I Z-R3 ??I, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.Type: ApplicationFiled: September 22, 2004Publication date: February 24, 2005Inventors: Michael Schrimpf, Kevin Sippy, Jerome Daanen, Keith Ryther, Jianguo Ji